Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

AstraZeneca to Build $200 Million Manufacturing Plant in China Medical City

publication date: Oct 10, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
AstraZeneca will spend $200 million to build a major new manufacturing facility in Taizhou’s China Medical City. The plant, which will produce both IV and solid oral medications for the China market, is the largest investment AstraZeneca has ever made in a single manufacturing site. China is becoming increasing important to AstraZeneca. In the first half of 2011, the company’s revenues in the PRC grew 22% to $624 million. More details....

Stock Symbol: (NYSE: AZN)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners